| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PARS2 |
| Uniprot No | Q7L3T8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-475aa |
| 氨基酸序列 | H HCAPRRGRRL LLSRVFQPQN LREDRVLSLQ DKSDDLTCKS QRLMLQVGLI YPASPGCYHL LPYTVRAMEK LVRVIDQEMQ AIGGQKVNMP SLSPAELWQA TNRWDLMGKE LLRLRDRHGK EYCLGPTHEE AITALIASQK KLSYKQLPFL LYQVTRKFRD EPRPRFGLLR GREFYMKDMY TFDSSPEAAQ QTYSLVCDAY CSLFNKLGLP FVKVQADVGT IGGTVSHEFQ LPVDIGEDRL AICPRCSFSA NMETLDLSQM NCPACQGPLT KTKGIEVGHT FYLGTKYSSI FNAQFTNVCG KPTLAEMGCY GLGVTRILAA AIEVLSTEDC VRWPSLLAPY QACLIPPKKG SKEQAASELI GQLYDHITEA VPQLHGEVLL DDRTHLTIGN RLKDANKFGY PFVIIAGKRA LEDPAHFEVW CQNTGEVAFL TKDGVMDLLT PVQTV |
| 预测分子量 | 53,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PARS2重组蛋白的模拟参考文献示例(实际文献需通过学术数据库查询)：
---
1. **标题**: *Structural and functional characterization of human PARS2 recombinant protein in mitochondrial translation*
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌表达系统纯化人源PARS2重组蛋白，解析其晶体结构并验证其催化脯氨酰-tRNA合成的酶活性，为线粒体翻译机制提供新见解。
2. **标题**: *PARS2 mutations impair mitochondrial protein synthesis via disrupted tRNA charging activity*
**作者**: Lee JH, et al.
**摘要**: 通过构建PARS2重组蛋白及突变体，发现与婴儿癫痫相关的基因突变会显著降低其氨基酰化活性，导致线粒体呼吸链复合体功能障碍。
3. **标题**: *Expression and purification of recombinant PARS2 for drug screening in neurodegenerative disorders*
**作者**: Chen R, et al.
**摘要**: 开发了昆虫细胞表达系统生产高纯度PARS2蛋白，用于高通量筛选靶向该酶的化合物，以探索其在神经退行性疾病中的治疗潜力。
4. **标题**: *Comparative analysis of PARS2 orthologs reveals evolutionary conservation in prokaryotic and eukaryotic systems*
**作者**: Gupta S, et al.
**摘要**: 对比不同物种PARS2重组蛋白的功能和结构，发现其催化核心高度保守，为研究氨基酰-tRNA合成酶的进化提供依据。
---
建议通过PubMed或Web of Science检索关键词“PARS2 recombinant”或“PARS2 prolyl-tRNA synthetase”获取最新文献。
The PARS2 (Prolyl-tRNA Synthetase 2) gene encodes a mitochondrial aminoacyl-tRNA synthetase critical for protein translation within mitochondria. Specifically, PARS2 catalyzes the attachment of proline to its cognate tRNA, a vital step in mitochondrial protein synthesis. As part of the evolutionary conserved aminoacyl-tRNA synthetase family, PARS2 ensures the fidelity of mitochondrial gene expression, supporting oxidative phosphorylation (OXPHOS) and cellular energy production. Mutations in PARS2 are linked to severe mitochondrial disorders, often presenting as early-onset neurodevelopmental conditions, including epilepsy, encephalopathy, and brain atrophy. These pathologies arise from impaired mitochondrial translation, leading to OXPHOS deficiencies and dysfunctional energy metabolism in high-demand tissues like the brain.
Recombinant PARS2 protein, generated via heterologous expression systems (e.g., E. coli or mammalian cells), serves as a key tool for studying its enzymatic activity, structure, and interaction partners. By purifying the recombinant protein, researchers can analyze the functional consequences of disease-associated mutations in vitro, elucidating mechanisms underlying mitochondrial dysfunction. Additionally, recombinant PARS2 aids in drug discovery, enabling high-throughput screening for compounds that modulate its activity or stabilize pathogenic variants. Its application extends to structural studies (e.g., X-ray crystallography) to map catalytic domains and tRNA-binding regions, offering insights into substrate specificity. Furthermore, recombinant PARS2 is utilized in diagnostic assays to evaluate tRNA charging deficiencies in patient-derived samples. As mitochondrial diseases lack curative therapies, understanding PARS2’s role through recombinant protein studies holds promise for developing targeted treatments, gene therapies, or biomarkers for early diagnosis. This underscores its importance in bridging molecular insights with clinical applications in mitochondrial medicine.
×
